-transparent.png){kind=logo}
1 Labetalol is an effective agent in essential hypertension as documented in open studies and controlled studies in which its efficacy has been compared with both placebo and a variety of other anti-hypertensive drugs. 2 Labetalol given by mouth lowers blood pressure rapidly. There is no evidence of tolerance to its anti-hypertensive action. 3 Adverse effects include excessive hypotension, but only when the drug is given in large doses. Epigastric discomfort and scalp tingling have been documented especially after intravenous administration. 4 From a pharmacokinetic and pharmacodynamic point of view, labetalol can be given once daily, but postural hypotension after large (greater than 1 g) single doses may limit the usefulness of once daily regimes. Twice daily administration appears an acceptable compromise.
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
January 1980,
Journal of cardiovascular pharmacology,
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
January 1980,
Current medical research and opinion,
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
February 1983,
Clinical pharmacology and therapeutics,
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
February 1987,
International journal of clinical pharmacology, therapy, and toxicology,
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
October 1983,
The American journal of medicine,
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
June 1991,
Journal of clinical pharmacology,
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
January 1979,
Acta medica Scandinavica. Supplementum,
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
February 1982,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
July 1990,
Journal of the Indian Medical Association,
A Breckenridge, and
M Orme, and
M J Serlin, and
M Maciver
April 1977,
Lancet (London, England),
